Oral Nutritional Supplementation and Weight Changes During Therapy in Malnourished Patients With Resistant Tuberculosis: A Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Tuberculosis (TB) is linked to poverty, malnutrition, and reduced immunity, with malnutrition both contributing to and resulting from TB.1-3 Active TB increases energy needs, causes protein breakdown, and leads to muscle wasting. Malnutrition, which is common in TB patients, worsens clinical outcomes and increases the risk of death.1 TB treatments can also cause nausea and vomiting, further contributing to malnutrition.4 Thus integrated management is essential for successful treatment.
In India, 68.6% of MDR-TB patients without HIV infection are malnourished, a prevalence comparable to that observed among MDR-TB patients at Persahabatan General Hospital, Jakarta, Indonesia (51.8%).5,6 Malnourished MDR TB patients have worse clinical outcomes, more side effects, and a higher risk of death.7 A BMI under 18.5 kg/m2 and inadequate weight gain during treatment indicate a poor response and increased risk of recurrence.1 Failure to gain weight (≤ 5%) in the first two months of treatment has been demonstrated to be linked to TB recurrence.8 Oral nutritional supplements have demonstrated the potential to improve nutritional status, muscle strength, and immunity, thus potentially facilitating an accelerated treatment process. Studies have also shown that nutritional supplements can improve BMI and gamma interferon levels.9 However, some studies have indicated that despite increased macronutrient intake, MDR TB patients may still experience a decline in body weight.10 This study aims to evaluate whether oral nutritional supplements providing 705 kcal and 30.5 grams of protein daily during the first two months can increase body weight and improve other clinical outcomes of MDR TB patients, including the impact of supplementation on albumin, globulin, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
DKI Jakarta
-
Jakarta, DKI Jakarta, Indonesia, 13230
- Rumah Sakit Umum Pusat Persahabatan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Who had access to electronic devices (e.g., mobile phones) for adherence monitoring
- individuals newly diagnosed with rifampicin-resistant pulmonary tuberculosis (RR-TB), multidrug-resistant tuberculosis (MDR-TB), or pre-extensively drug-resistant tuberculosis (Pre-XDR-TB) at the drug-resistant tuberculosis outpatient clinic of Persahabatan General Hospital, Jakarta, Indonesia.
- BMI of 13-20 kg/m²
- had received standardized or individualized treatment regimens for seven days
- had no severe drug-induced hepatitis indicated by elevated liver enzymes >5 times the normal upper limit
Exclusion Criteria:
- individuals with HIV infection,
- end-stage renal failure,
- severe anemia (hemoglobin <8 g/dL),
- severe hypoalbuminemia (albumin <2.5 g/dL),
- acute or chronic liver diseases (including hepatitis, cirrhosis, or jaundice),
- cancer,
- interstitial lung disease (ILD),
- anatomical gastrointestinal disorders (either congenital or post-surgical),
- diabetes mellitus,
- long-term corticosteroid or immunosuppressant therapy
- other acute pulmonary infections such as pneumonia,
- exacerbations of chronic obstructive pulmonary disease (COPD), or asthma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention group
standard Oral Nutritional Supplement (ONS) in the form of a soy-based drink (235 kcal/200mL: 10.34 g protein, 7.9 g fat, 30.61 g carbohydrate; Protein; Otsuka) with the instruction to consume three (3) sachets per day (total of 705 kcal and 31 grams of protein) plus standard treatment.
|
Oral Nutritional Supplement (ONS) in the form of a soy-based drink (235 kcal/200mL: 10.34 g protein, 7.9 g fat, 30.61 g carbohydrate; Protein)
|
|
No Intervention: Control group
standard treatment only
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight
Time Frame: Pre intervention and post intervention (at 60 days)
|
A change in body weight in kg
|
Pre intervention and post intervention (at 60 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily food intake
Time Frame: From enrollment to 60 days after enrollment
|
Daily food intake of total energy, protein, fat, and carbohydrates.
The subjects were given a form to record food intake 3 times a week (2 working days and 1 day off) for 8 weeks including the type and amount of food measured using standard units of spoons, glasses, etc.
Furthermore, the intake data was converted into grams using a food ingredient analysis list and then analyzed using the 2007 nutrisurvey.
|
From enrollment to 60 days after enrollment
|
|
Albumin
Time Frame: Pre intervention and post intervention (at 60 days)
|
Serum albumin is measured by taking peripheral venous blood samples with units of g/dL.
|
Pre intervention and post intervention (at 60 days)
|
|
CRP
Time Frame: Pre intervention and post intervention (at 60 days)
|
CRP is measured by taking peripheral venous blood samples in mg/dL units.
|
Pre intervention and post intervention (at 60 days)
|
|
Total protein
Time Frame: Pre intervention and post intervention (at 60 days)
|
Total protein is measured using a peripheral venous blood sample in g/dL units.
|
Pre intervention and post intervention (at 60 days)
|
|
ESR
Time Frame: Pre intervention and post intervention (at 60 days)
|
Erythrocyte sedimentation rate is measured using a peripheral venous blood sample in mm/hour units.
|
Pre intervention and post intervention (at 60 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Fathiyah Isbaniah Sp.P(K), Dr., dr., Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Indonesia, Persahabatan General Hospital, Jakarta
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 25/UN2.F1/ETIK/PPM.00.02/2022
- Otsuka Holding (Other Identifier: Oral Nutritional Supplementation)
- Global Fund to Fight AIDS, TB (Other Identifier: Infection Disease)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.